{"filing":{"accession_number":"0001193125-26-384430","cik":"0000863894","ticker":"VERU","company_name":"VERU INC.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"d543118d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/863894/000119312526384430/d543118d8k.htm"},"events":[{"id":31831,"run_id":29230,"accession_number":"0001193125-26-384430","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Veru announced a strategic shift in its drug development pipeline: advancing sabizabulin into Phase 2b clinical trials for daraxonrasib-resistant metastatic pancreatic cancer based on new positive preclinical data, while discontinuing exploration of sabizabulin for atherosclerotic cardiovascular disease. This represents a material operational and strategic decision affecting the company's pipeline priorities and resource allocation, but does not fit the specific categories of M\u0026A, impairment, litigation, or other defined event types. The decision is material to investors as it redirects development efforts toward a potentially significant oncology indication with unmet medical need.","company_name":"VERU INC.","ticker":"VERU","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34841,"accession_number":"0001193125-26-384430","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Veru announced a strategic shift in its drug development pipeline: advancing sabizabulin into Phase 2b clinical trials for daraxonrasib-resistant metastatic pancreatic cancer based on new positive preclinical data, while discontinuing exploration of sabizabulin for atherosclerotic cardiovascular disease. This represents a material operational and strategic decision affecting the company's pipeline priorities and resource allocation, but does not fit the specific categories of M\u0026A, impairment, litigation, or other defined event types. The decision is material to investors as it redirects development efforts toward a potentially significant oncology indication with unmet medical need.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:19:08.925923+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34841,"accession_number":"0001193125-26-384430","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Veru announced a strategic shift in its drug development pipeline: advancing sabizabulin into Phase 2b clinical trials for daraxonrasib-resistant metastatic pancreatic cancer based on new positive preclinical data, while discontinuing exploration of sabizabulin for atherosclerotic cardiovascular disease. This represents a material operational and strategic decision affecting the company's pipeline priorities and resource allocation, but does not fit the specific categories of M\u0026A, impairment, litigation, or other defined event types. The decision is material to investors as it redirects development efforts toward a potentially significant oncology indication with unmet medical need.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:19:08.925923+00:00","company_name":"VERU INC.","ticker":"VERU","filing_date":"2026-09-08"}]}